Zhitong Finance App News, Shijiyao Group (02005) announced that the Group's nanofloxacin malate has been approved by the China National Drug Administration and registered as an active ingredient for use in marketed formulations.

Ninofloxacin malate is an anti-infective drug mainly used to treat adult community-acquired pneumonia caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus parainfluenzae, Mora catarrhalis, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Mycoplasma pneumoniae, and Legionella pneumophila.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.